Search Results (425)

Exocrine pancreatic insufficiency (EPI) is a chronic gastrointestinal disease in dogs that is caused by the insufficient synthesis and secretion of pancreatic digestive enzymes by the exocrine pancreas. Previous studies have described intestinal dysbiosis in dogs with EPI and dysbiosis is often associated with bile acid dysmetabolism. This study aimed to measure the concentration of a variety of bile acids in the serum of dogs with EPI. Serum was collected from 50 dogs with a serum canine trypsin-like immunoreactivity (cTLI) concentration of less than 1 µg/L, strongly suggesting EPI, and 50 non-EPI control dogs with a serum cTLI concentration within the reference interval. Half of the dogs with EPI and half the non-EPI control dogs were German shepherd dogs and half were dogs of other breeds. There were significant differences in serum bile acid concentrations between non-EPI control dogs and dogs with EPI. Dogs with EPI had significantly higher serum concentrations of both primary and total bile acids. This study shows that EPI in dogs is associated with bile acid dysmetabolism. Full article

Inflammation is a central pathological process in many chronic diseases and is closely linked to tissue injury and organ dysfunction. Although anti-inflammatory drugs are widely used in clinical practice, their long-term application can be limited by adverse effects and inadequate efficacy, creating a need for safer and more effective therapeutic approaches. Allicin, the principal bioactive organosulfur compound derived from garlic, has attracted increasing research interest because of its anti-inflammatory and antioxidant activities. Preclinical evidence indicates that allicin can attenuate inflammatory responses, inhibit inflammatory cell activation, reduce oxidative stress, and limit tissue damage in various disease models. Protective effects have been reported in models involving the digestive, respiratory, cardiovascular, urinary, and nervous systems. This review summarizes the preclinical evidence for the anti-inflammatory effects of allicin across these organ systems, focusing on the underlying molecular mechanisms, shared signaling pathways, and organ-associated features. The chemical instability, rapid metabolism, and poor oral bioavailability of allicin remain important barriers to clinical translation, while high-quality clinical evidence from studies of purified allicin in humans remains limited. These challenges, together with potential strategies for overcoming them, are also discussed. Full article

Background: The aim of this study was to assess long-term trends in mortality due to digestive diseases among older adults in Poland. Methods: Mortality data for the years 2000–2022 were analyzed for individuals aged ≥65 years. Age-standardized death rates (SDRs) were calculated. Particular attention was paid to liver cirrhosis-related mortality, operationalized according to the tenth revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) joined categories K70 and K74. Temporal trends were assessed using joinpoint regression to estimate annual percentage change (APC) and average annual percentage change (AAPC) stratified by sex and age groups (65–74 and ≥75 years). The total number of deaths included in the statistical analysis was 6,645,408. Results: In early old age (65–74 years), the proportion of deaths due to digestive diseases increased in both men (from 3.6% to 5.0%) and women (from 4.1% to 4.5%), while a decrease was observed in late old age (≥75 years). The combined K70/K74-coded liver disease category represented an important component of digestive disease mortality. Among women aged 65–74 years, a significant upward trend in SDR was observed after 2015 (APC 3.5%, p < 0.05), with an increase from 54.7 to 70.8. In men of the same age, SDR remained relatively stable overall (160.5 to 171.6), although mortality due to liver-related diseases increased significantly after 2015 (APC 6.7%, p < 0.05). In older age groups, declining trends were observed until the late 2010s, followed by recent non-significant increases. Conclusions: Mortality patterns for alcohol-related liver disease and hepatic fibrosis/cirrhosis showed particularly unfavorable recent trends in adults aged 65–74 years. These findings highlight the need for continued surveillance and prevention of chronic liver disease in ageing populations. Full article

Tagetes erecta L. is an important industrial source of lutein and other phytochemicals with antioxidant, anti-inflammatory, and glucose- and lipid-metabolizing potential. This review analyzes its phytochemical composition, biological mechanisms, potential applications in the prevention of chronic non-communicable diseases, and emerging uses of nanotechnology to enhance biomass and secondary metabolite production. A structured search was conducted in PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar using terms related to T. erecta, carotenoids, flavonoids, metabolic health, nanoparticles, nanoelicitation, and agro-industrial valorization. The evidence indicates that lutein, zeaxanthin, quercetagetin derivatives, patuletin, quercetin, and phenolic acids can modulate oxidative stress, inflammatory signaling, carbohydrate-digesting enzymes, lipid accumulation, and cell protection. Furthermore, the flowers, leaves, and extraction residues can be used as reducing and stabilizing matrices for the sustainable synthesis of functional nanomaterials. Nanoelicitors, nanofertilizers, and nanoencapsulated systems could stimulate the methylerythritol phosphate pathway, chromoplast differentiation, and the expression of genes related to carotenoid biosynthesis. Taken together, T. erecta represents a promising platform for the development of nutraceuticals, nanobiotechnology, and circular bioeconomy applications; however, phytochemical standardization, clinical validation, mechanistic studies supported by omics sciences, and pilot-scale evaluations are still required. Full article

High-amylose starch (HAS) is composed predominantly of linear α-1,4-linked glucose units and is high in resistant starch content. Its unique physicochemical properties and gut fermentation dynamics confer multiple health benefits. This review summarizes HAS digestion, its interactions with gut microbes, and its systemic effects. HAS intake can reshape the gut microbiota by enriching beneficial taxa such as Bifidobacterium, Faecalibacterium, and Akkermansia, while suppressing harmful bacteria like Escherichia coli and Clostridium difficile. These microbial shifts enhance short-chain fatty acid production, improve gut barrier integrity, and reduce inflammation. HAS also demonstrates therapeutic potential in obesity, type 2 diabetes, chronic kidney disease, and colorectal cancer by improving insulin sensitivity, reducing glycemic variability, and modulating oncogenic pathways. Collectively, dietary incorporation of HAS represents a promising functional strategy to support gut and systemic health across diverse physiological contexts. Full article

Interest in sustainable protein sources is increasing because of environmental concerns related to animal agriculture and the growing burden of chronic non-communicable diseases. Plant-derived bioactive peptides (PDBAPs), amino acid sequences released from dietary proteins, are gaining attention because experimental studies have reported activities relevant to hypertension, type 2 diabetes, and cancer-associated processes. Although animal proteins have long been major sources of bioactive peptides, plant materials may offer advantages such as abundance, potentially lower production costs, and broad cultural acceptability; however, these benefits depend on the source, processing requirements, safety, and scale-up conditions. This review integrates plant sources, processing technologies, proposed mechanisms of action, and translational barriers. Current research covers traditional sources, including legumes and cereals, as well as agro-industrial by-products such as potato peels, spent coffee grounds, and broccoli stems. Modern processing strategies increasingly combine enzymatic hydrolysis or microbial fermentation with process-assisting technologies, including ultrasound treatment and subcritical water processing, to improve protein recovery or peptide release. Recent studies also examine proposed mechanisms of PDBAP activity, including Keap1/Nrf2-associated responses and inhibition of enzymes involved in metabolic disorders. Evidence is interpreted according to the stage of experimental validation, from computational prediction and cell-free assays to cellular, animal, and human studies. Key challenges remain, particularly digestive instability, uncertain systemic bioavailability, bitterness, safety standardization, and limited human clinical evidence. Future work should prioritize standardized extraction and analytical methods, optimized delivery systems, and robust clinical trials. Full article

Obesity is a heterogeneous chronic disease for which safe, scalable adjuncts to lifestyle and clinical care remain needed. Tea derived from Camellia sinensis contains catechins, caffeine, theaflavins, thearubigins, theabrownins, polysaccharides, and other constituents whose abundance is shaped by withering, fixation, partial oxidation, full oxidation, and post-fermentation. This review integrates processing-dependent composition with molecular mechanisms, gut–liver signaling, human evidence, safety, and real-world preparation. Evidence is strongest for modest effects of green-tea catechin–caffeine preparations on energy metabolism and selected anthropometric or lipid outcomes, whereas inhibition of adipogenesis, activation of AMP-activated protein kinase, browning of white adipose tissue, and many appetite-related pathways remain supported mainly by cell and rodent studies. A recent meta-analysis in women with overweight or obesity estimated mean reductions of −1.23 kg in body weight and −3.46 cm in waist circumference, with intervention durations across the included trials typically ranging from 4 to 24 weeks, though most of the evidence derives from short- to medium-term interventions (generally ≤12 weeks); heterogeneity was moderate to high and the average weight effect remained below conventional clinical thresholds. Partially oxidized oolong tea and fully oxidized or post-fermented teas provide distinct profiles of caffeine, oxidized polyphenols, and microbial metabolites; their metabolic effects are promising but are less consistently tested in adequately powered human trials. Across tea types, convergent mechanisms include reduced digestive-enzyme activity, increased fatty-acid oxidation, modulation of thermogenesis, reinforcement of the intestinal barrier, and microbiota-dependent production of short-chain fatty acids and bile-acid signals. Translation is constrained by low systemic polyphenol exposure (i.e., limited bioavailability of intact catechins and their metabolites in circulation due to poor intestinal absorption, extensive phase-II metabolism, and rapid clearance), non-standardized doses and products, short intervention periods, interindividual variability, and limited direct comparisons among tea types. Available clinical data do not support tea as a primary treatment for obesity; rather, unsweetened tea or standardized preparations may serve as adjuncts to evidence-based dietary, physical activity, behavioral, and medical management. Priority areas include physiologically relevant dosing, standardized reporting of brewed-tea composition, long-term trials, and microbiome-informed personalization. Full article

Mast cells (MCs) are immune cells that produce numerous immunological mediators involved in inflammatory and allergic responses. Increased numbers of MCs are observed in chronic inflammatory reactions in organs such as the colon. There, MCs seem to participate in deleterious immune responses and tissue damage, but the detailed mechanisms of their activation are not known, mostly because procedures to obtain MC primary cultures from the colonic mucosa are expensive and time-consuming and present low yield. Here we describe a protocol to obtain MCs from the colonic mucosa (cmMCs) of C57BL/6 mice with high yield, viability and purity. Mucosal colon cells were dispersed by enzymatic digestion, and cmMCs were isolated by Percoll continuous-gradient centrifugation. This method allowed for the purification of 1,446,667 ± 112,442 cell/g of mucosal tissue, with 87.22% viability and 95.16% purity. The mucosal-like phenotype was predominant in isolated cmMCs, characterized by weak toluidine blue staining but strong expression of MC protease-1 (Mcpt1). Activation assays showed that freshly isolated cmMCs increased intracellular calcium and showed degranulation in response to ATP or IgE-antigen-dependent FcεRI cross-linking. This highly reproducible technique is cost-effective and requires no specialized equipment. This protocol could be applied in research related to inflammatory bowel disease, colon cancer or food allergies. Full article

Ulcerative colitis (UC) is a chronic inflammatory bowel disease marked by immune dysregulation, microbiota imbalance, and intestinal barrier damage. Unconjugated bilirubin (UCB) shows promise in treating UC due to its anti-inflammatory properties but is limited by poor solubility and potential toxicity. This study developed a chitosan-based controlled-release microsphere (CBMS) treatment to overcome these issues. CBMS utilizes the mucoadhesive properties of chitosan to achieve targeted, controlled UCB release in the colon, enhancing its stability and bioavailability. In a DSS-induced UC mouse model, CBMS alleviated clinical symptoms, reduced colon shortening, and improved histological outcomes, including reduced inflammation and enhanced mucosal repair. The mechanism involves CBMS retention in the intestinal lumen, UCB inactivation of digestive proteases, and restoration of microbiota balance, suppressing pro-inflammatory pathways. CBMS offers a promising new therapeutic strategy for UC and insights into polysaccharide-based drug delivery systems. Full article

Climate change is increasing the frequency, intensity, and duration of heatwaves, making extreme heat a recurrent public health challenge with important nutritional implications. High ambient temperatures affect human health through thermoregulatory strain, sweating, dehydration, electrolyte imbalance, cardiovascular and renal stress, impaired cognitive and physical performance, and exacerbation of chronic diseases. Diet and hydration may therefore represent modifiable, although still underinvestigated, components of heat-health prevention. This narrative review synthesizes evidence on hydration, electrolyte balance, meal composition, dietary quality, vulnerable populations, Mediterranean dietary patterns, seasonality, environmental sustainability, and public health strategies for reducing heat-related health risks. Evidence from climate-health research, physiology, nutrition science, occupational and sports medicine, geriatrics, pediatrics, and public health guidance was integrated. Particular attention was given to distinguishing direct heat-health evidence from recommendations based on indirect evidence, physiological plausibility, or expert consensus. Regular water intake, water-rich foods, avoidance of alcohol, moderation of sugar-sweetened beverages, and individualized electrolyte replacement during prolonged or intense sweating are supported by physiological rationale and public health guidance, although direct heatwave-specific intervention studies remain limited. Dietary recommendations should prioritize smaller, digestible, nutrient-dense meals that preserve nutritional adequacy while reducing unnecessary digestive and metabolic burden. However, evidence on meal size, macronutrient composition, and heat-related outcomes remains largely indirect. Vulnerable groups, including older adults, children, pregnant women, individuals with chronic diseases, outdoor workers, athletes, and socioeconomically disadvantaged populations, require tailored strategies. The Mediterranean diet may provide a useful regional model because it emphasizes seasonal plant foods, fruits and vegetables with high water content, legumes, whole grains, olive oil, culinary simplicity, and environmental sustainability; however, its specific role in heat adaptation requires further study. Integrating nutrition and hydration into heat-health action plans may improve preparedness and support climate-resilient food systems. Future studies should evaluate hydration protocols, meal patterns, Mediterranean diet adherence, biomarkers of nutritional heat resilience, and nutrition-sensitive interventions in real-world heat exposure settings. Full article

Background: Type 2 diabetes (T2DM) is a chronic metabolic disease closely associated with insulin resistance (IR) and disturbances in glucose and lipid metabolism. Bioactive peptides derived from food are attracting increasing research attention as candidates for nutritional supplements or functional food ingredients that improve metabolic health. This study evaluated the functional food-related properties of YPWTQ (CP4), a novel peptide derived from donkey blood, and its ability to alleviate insulin resistance in HepG2 cells. Methods: CP4 was characterized based on its hemolytic activity, stability under simulated gastrointestinal digestion conditions, inhibitory activity against α-glucosidase and Pancreatic lipase, and free radical scavenging capacity (DPPH·, ABTS⁺·, and O₂⁻·). Its effects on glucolipid metabolism and oxidative stress were examined in a glucosamine-induced insulin-resistant HepG2 cell model. Candidate signaling pathways associated with CP4 treatment were explored through transcriptomic and metabolomic analyses, combined with RT-qPCR technology. Results: CP4 exhibited low hemolytic activity and remained stable after 4 h of simulated gastrointestinal digestion. It inhibited α-glucosidase and Pancreatic lipase and exhibited antioxidant activity. In insulin-resistant HepG2 cells, CP4 increased glucose consumption, glycogen content, and cell survival, while reducing triglyceride accumulation, malondialdehyde levels, and reactive oxygen species (ROS) production. Mult omics analysis indicates that these phenotypic effects may be associated with coordinated changes in the PI3K-Akt, AGE-RAGE, Rap1, and Ras signaling pathways, as well as related genes and metabolites. Conclusions: These findings suggest that CP4, as a food-derived bioactive peptide candidate, warrants further investigation into its potential applications in the field of metabolic health. Full article

Medium-chain triglycerides (MCTs) are functional lipids with unique physicochemical properties and metabolic advantages. Recently, their regulatory roles in various chronic diseases have attracted considerable attention. This review systematically summarizes recent research progress and the proposed mechanisms of MCTs and their metabolites in metabolic diseases, neurological disorders, gut health, and muscle function. In the metabolic field, MCTs offer potential nutritional strategies for managing obesity, type 2 diabetes mellitus (T2DM), and various metabolic liver diseases. These effects are primarily mediated by improving insulin sensitivity, regulating lipid metabolism, and modulating energy expenditure. In neurological diseases, MCTs demonstrate potential for preventing and treating Alzheimer’s disease (AD), Parkinson’s disease (PD), and epilepsy through multiple pathways, including ketogenic energy supply, anti-inflammatory and antioxidant effects, and mitochondrial protection. Regarding gut health, MCTs and their derivatives may benefit digestive health by modulating gut microbiota and enhancing barrier function. For muscle health, MCTs help optimize energy metabolism and protein homeostasis, showing promise for countering sarcopenia and improving exercise performance. In conclusion, the prospects for MCTs are broad. Future research should focus on promoting their scientific application in precision nutrition and disease therapy, and more rigorous clinical trials are needed to confirm their efficacy and safety. Full article

Type 2 diabetes (T2D), a major global health challenge, represents approximately 96% of all cases of diabetes worldwide. Epidemiological forecasts indicate the prevalence of this disease could rise by almost 45% over the next 25 years. T2D is a chronic metabolic disorder characterised by insulin resistance and progressive impairment of β-cell function. Untreated T2D can lead to serious microvascular and macrovascular complications. Traditional therapies have focused primarily on glycaemic control, whereas modern treatment strategies are increasingly centred on the broader pathophysiology of T2D. Among new therapeutic approaches, triazine derivatives have gained significant attention as versatile scaffolds for the development of antidiabetic drugs. This article provides a comprehensive review of triazines (mainly 1,2,4-triazines and 1,3,5-triazines) as promising compounds for the treatment of T2D and its complications. Three databases (Scopus, PubMed, and Web of Science) were searched for the period of 2000–2025. Over the past 25 years, numerous compounds have been described. They were primarily investigated as inhibitors of digestive enzymes and factors that cause diabetic complications. The individual sections discuss the biological activity of these compounds, focusing on SAR analysis and the studies conducted (in vitro, in silico, and in vivo). During this period, two compounds, fotagliptin and imeglimin, have entered clinical use. The results show that triazines have great potential to become antidiabetic drugs. They can not only regulate blood sugar levels (by acting on digestive enzymes, insulin secretion or glucose transport) but also directly prevent serious complications of diabetes. Full article

Background: Chronic enteropathy associated with the SLCO2A1 gene (CEAS) is a rare disease characterized by multiple small intestinal ulcers whose pathogenesis remains poorly understood. This study aimed to characterize the proteomic and phosphoproteomic profiles of CEAS and to identify molecular pathways involved in its pathogenesis. Methods: Quantitative proteomics and phosphoproteomics were performed on intestinal mucosal tissues from patients with CEAS (n = 3), Crohn’s disease (CD, n = 3), and healthy controls (n = 3). Differentially expressed proteins (DEPs) and differentially phosphorylated proteins (DPPs) were analyzed using functional enrichment, gene set enrichment analysis (GSEA), protein–protein interaction (PPI) networks, and integrative analysis. Results: A total of 900 DEPs were identified in CEAS and 277 in CD relative to controls, including 717 CEAS-specific proteins. CEAS-specific alterations were strongly enriched in focal adhesion and extracellular matrix-related pathways, whereas shared proteins between CEAS and CD were primarily associated with epithelial barrier function, including tight junction and adherens junction pathways. GSEA revealed that CEAS was characterized by upregulation of tissue remodeling and focal adhesion pathways, accompanied by suppression of digestive and metabolic processes, while CD exhibited prominent adaptive immune activation. PPI network analysis identified POSTN, CDH1, TLN1, and VIM as candidate hub proteins; however, none retained significance after FDR correction, whereas brush-border components (CDHR2, MUC3A, MUC13, ALPI) and actin cytoskeletal regulators remained the most statistically robust alterations. Integrated analysis further highlighted focal adhesion-related proteins with coordinated expression and phosphorylation changes. Conclusions: This exploratory study provides the first integrative proteomic and phosphoproteomic characterization of CEAS, suggesting that impairment of the intestinal brush border and mucosal barrier, together with actin cytoskeletal reorganization, may distinguish CEAS from immune-dominant CD. These findings are hypothesis-generating and require validation in larger cohorts. Full article

The digestive system is one of the most complex systems in the body, integrating multiple functions, closely linked to and influenced by chemosensory mechanisms, as well as by the presence, composition, and dynamics of the microbiome. Increasing attention has been directed toward plant-derived foods and medicines, which interact with gut microbiota and modulate host physiological responses through microbial metabolism, leading to the formation of bioactive metabolites that influence host signaling pathways and therapeutic response. The review, based on relevant articles from major international databases using specific terms with a focus on microbiome-mediated interactions and molecular mechanisms, highlights the role of microbiome and diagnostic methods through the analysis of specific composition and changes in microbiota, as well as the importance of microbiomes in relation to the treatment of chronic diseases, given their complex influence on drug metabolism. The microbiome influences the response to medications and resistance to therapy, being also involved in the metabolism of plant-derived foods and medicines through complex microbial interactions, while the importance of modern diagnostic approaches supports the use of microbiome analysis to improve diagnosis, monitoring, and personalized medical strategies. Full article